Discover

SLXN
Silexion Therapeutics Corp
2.58
2 x 1.89
2 x 3.34
bid
ask
+
0.04
1.37%
2 @ 06:14 AM
2.58 -0.00 (0.19%)
Ytd-86.54%
1y-97.85%
2.55
day range
2.68
2.31
52 week range
223.60
Open2.56Prev Close2.55Low2.55High2.68Mkt Cap2.75M
Vol23.84KAvg Vol638.49KEPS-59.70P/EN/AForward P/E-3.95
Beta-0.11Short Ratio0.23Inst. Own8.15%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0750-d Avg4.70200-d Avg19.011yr Est9.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-142024-090-18.27N/AN/A
2011-05-162011-030N/AN/AN/A
2011-03-082010-120N/AN/AN/A
2010-12-062010-090N/AN/AN/A
2010-09-032010-060N/AN/AN/A
2010-06-042010-030N/AN/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-11-01Maxim GroupUpgradeBuy
Profile
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Wildcat Capital Management, LLC113.43K286.97K0.79%
2024-09-29HRT Financial LP10.00K25.29K0.07%
2024-09-29Virtu Financial LLC2.96K7.49K0.02%
2024-09-29Two Sigma Securities, LLC1.68K4.25K0.01%
2024-09-29UBS Group AG1.67K4.23K0.01%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-10-30Fidelity NASDAQ Composite Index Fund587.001.49K0.00%